Jonathan Plehn

Jonathan Plehn

Company: Sardocor

Job title: Chief Medical Officer


Genetic Lusitropic Therapy: Modulation of SERCA2a in HFpEF 4:15 pm

The role of SERCA2a on calcium trafficking, ventricular relaxation (lusitropy) and the complex mechanisms of diastolic dysfunction in HFpEF will be discussed Description of the evidence for lusitropic improvement via enhancement of SERCA2a activity in animal models of HFpEF Presentation of the design of the first gene therapy trial in HFpEF patients to enhance the…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.